Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACTIL vs AMITRIPTYLINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Major depressive disorder
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Primarily hepatic via CYP2D6 and other microsomal enzymes; active metabolite desmethylprotriptyline.
Primarily hepatic via CYP2D6, CYP3A4, CYP1A2, and CYP2C19; active metabolite nortriptyline; undergoes demethylation, hydroxylation, and conjugation.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Approximately 90% bound, primarily to albumin and α1-acid glycoprotein.
Approximately 94-96%; primarily bound to alpha-1-acid glycoprotein (AAG), with minor binding to albumin and lipoproteins.
Vd approximately 8–15 L/kg, indicating extensive tissue distribution with higher CNS concentration than plasma.
10-20 L/kg (large Vd due to extensive tissue binding); clinical meaning: high tissue penetration, especially CNS, and slow redistribution from tissues.
Oral bioavailability approximately 30–40% due to first-pass metabolism (extensive hepatic cytochrome P450 biotransformation).
Oral: 30-60% due to extensive first-pass metabolism (CYP2C19, CYP3A4, CYP2D6); significant interindividual variability.
For GFR <10 m L/min: use with caution and consider 50% dose reduction; no specific guidelines for GFR 10-50 m L/min.
GFR 10-50 m L/min: use 50% of normal dose; GFR <10 m L/min: use 25% of normal dose.
Child-Pugh class B or C: reduce dose by 50-75%; avoid use in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for children <12 years; for adolescents 12-18 years: 5-10 mg orally twice daily, max 60 mg/day.
Adolescents: 10-50 mg daily in divided doses; children under 12 years (for enuresis): 6-10 years: 10-20 mg, 11+ years: 25-50 mg at bedtime.
Initiate at 5 mg orally twice daily; increase slowly with monitoring for orthostatic hypotension and anticholinergic effects.
Start at 10-25 mg at bedtime; increase by 10-25 mg every 3-7 days as tolerated; maximum 75-100 mg daily; monitor for CNS and anticholinergic effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is recommended.
Activation of mania/hypomania,Seizure threshold lowering,Cardiovascular toxicity (QT prolongation, arrhythmias),Angle-closure glaucoma,Urinary retention,Hepatic impairment,Concomitant MAOI use
Cardiotoxicity (QT prolongation, arrhythmias), serotonin syndrome, activation of mania/hypomania, angle-closure glaucoma, urinary retention, seizures, increased intraocular pressure, orthostatic hypotension, drowsiness, withdrawal symptoms upon abrupt discontinuation.
Hypersensitivity to protriptyline,Recent myocardial infarction,Concurrent MAOI therapy,QT prolongation or concomitant QT-prolonging drugs
Concurrent use with MAOIs (risk of serotonin syndrome), recent myocardial infarction, hypersensitivity to tricyclic antidepressants, during acute recovery phase of MI, use with cisapride or other QT-prolonging drugs.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) if taking with MAOIs; however, protriptyline alone has no significant tyramine interaction. Grapefruit juice may increase protriptyline levels; avoid high intake. Alcohol can potentiate CNS depression. High-fiber foods may slightly reduce absorption; take at same time each day.
Avoid alcohol and tyramine-rich foods (e.g., aged cheese, cured meats, soy sauce) due to risk of hypertensive crisis. Limit caffeine intake; may increase CNS stimulation. Grapefruit juice may increase plasma levels; avoid or limit consumption.
First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withdrawal, respiratory distress, tachycardia, and hyperirritability if used near term.
First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but possible effects on fetal growth. Third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and anticholinergic effects (constipation, urinary retention). Overall risk is low; benefits may outweigh risks in severe depression.
Present in breast milk; M/P ratio 0.5–1.9. Cases of drowsiness and poor feeding in infants reported; avoid breastfeeding or use with caution.
Amitriptyline and its metabolite nortriptyline are excreted in breast milk with an M/P ratio of approximately 1.0 for amitriptyline. Infant daily dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in most infants; however, monitor for drowsiness, poor feeding. American Academy of Pediatrics considers amitriptyline compatible with breastfeeding.
Decreased plasma concentrations due to increased volume of distribution; consider dose adjustment based on clinical response and serum levels; start at low dose and titrate.
Pregnancy increases clearance of amitriptyline by 30-50% due to expanded plasma volume and enhanced hepatic metabolism. Serum levels may decrease, potentially requiring dose increase of 30-50% to maintain efficacy. Consider therapeutic drug monitoring (target trough 100-250 ng/m L) for dose titration. Postpartum dosing should be reduced to prepregnancy levels.
VIVACTIL (protriptyline) is a tricyclic antidepressant with a more activating profile; it has the fastest onset of weight gain among TCAs. It is often used for ADHD, narcolepsy, and depression with psychomotor retardation. Due to its long half-life (54-92 hours), dosing should be conservative in elderly. It has a high anticholinergic burden, risking urinary retention and cognitive impairment in older adults. Avoid in patients with recent MI or arrhythmias. Monitor EKG and drug levels in suspected overdose.
Do not discontinue abruptly; taper over 2-4 weeks to prevent withdrawal symptoms. Use with caution in patients with cardiac conduction defects (prolongs QTc interval). Serum levels >500 ng/m L are associated with toxicity. Start at 10-25 mg at bedtime for neuropathic pain. May precipitate mania in bipolar disorder.
Take exactly as prescribed; do not stop suddenly as withdrawal may occur.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts or worsening depression immediately.,May cause dry mouth, constipation, blurred vision; use sugarless candy or gum for dry mouth.,Rise slowly from sitting or lying to prevent dizziness.,Do not take with MAOIs or within 14 days of stopping them.,Notify doctor if you experience fast/irregular heartbeat, difficulty urinating, or seizures.
Take at bedtime to minimize daytime sedation.,Avoid alcohol and other CNS depressants.,Report symptoms of urinary retention, vision changes, or rapid heartbeat.,May cause dry mouth; use sugar-free gum or candy.,Avoid abrupt discontinuation; follow your doctor's tapering plan.,Notify your doctor if you experience suicidal thoughts or worsening depression.
No interactions on record
"Amitriptyline, a tricyclic antidepressant, may inhibit the metabolism of captopril, an ACE inhibitor, leading to increased serum concentrations of captopril. This elevation can potentiate captopril's antihypertensive effects and increase the risk of adverse effects such as hypotension, renal impairment, and hyperkalemia. Patients should be monitored closely for signs of exaggerated hypotensive response and electrolyte disturbances."
"Rifapentine, a potent inducer of cytochrome P450 (CYP) enzymes, specifically CYP3A4 and CYP2C19, significantly increases the hepatic metabolism of amitriptyline, a tricyclic antidepressant primarily metabolized by CYP2C19 and CYP3A4. This induction leads to markedly reduced plasma concentrations of amitriptyline and its active metabolite nortriptyline, potentially resulting in loss of antidepressant efficacy or relapse of depressive symptoms. Additionally, abrupt withdrawal of rifapentine without dose adjustment of amitriptyline may cause increased tricyclic levels and toxicity."
"Dapiprazole, an alpha-1 adrenergic receptor antagonist, and amitriptyline, a tricyclic antidepressant with significant anticholinergic properties, can have additive anticholinergic and sympatholytic effects when coadministered. This may lead to enhanced central nervous system depression, hypotension, urinary retention, and constipation. Patients should be monitored for excessive sedation, orthostatic hypotension, and anticholinergic toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VIVACTIL vs AMITRIPTYLINE HYDROCHLORIDE, answered by our medical review team.
VIVACTIL is a Tricyclic Antidepressant that works by Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.. AMITRIPTYLINE HYDROCHLORIDE is a Tricyclic Antidepressant that works by Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIVACTIL and AMITRIPTYLINE HYDROCHLORIDE depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIVACTIL is: 10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.. The standard adult dose of AMITRIPTYLINE HYDROCHLORIDE is: Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIVACTIL and AMITRIPTYLINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIVACTIL is classified as Category C. First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withd. AMITRIPTYLINE HYDROCHLORIDE is classified as Category C. First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.